ABILIFY® (aripiprazole tablets)
- Atypical antipsychotic
- Dopamine system stabilizer
- Partial agonist on dopamine D2 and serotonin 5HT1A receptor, and antagonist on serotonin 5HT2A receptor
- ABILIFY® is indicated for:
- Treatment of schizophrenia in adult and adolescent patients aged 13 – 17 years
- Bipolar I disorder
- Acute treatment of manic or mixed episode in adult and pediatric patients aged 10 – 17 years*
- Maintenance treatment in adult*
* as monotherapy or as an adjunct to lithium or valproate
- Adjunctive treatment for major depressive disorder in adult
- Treatment of irritability associated with autistic disorder in pediatric patients aged 6 – 17 years
| Formulation | Package | Strength | Colour / Appearance |
|---|---|---|---|
| Tablets | 30 tablets/ box | 2 mg | Green modified rectangle tablet |
| 5 mg | Blue modified rectangle tablet | ||
| 10 mg | Pink modified rectangle tablet | ||
| 15 mg | Yellow round tablet | ||
| Orally Disintegrating Tablets |
30 tablets/ box | 10 mg | Pink (with scattered specks) round oral dispersible tablet |
| 15 mg | Yellow (with scattered specks) round oral dispersible tablet |
Abilify Maintena® (aripiprazole extended release injectable suspension)
- Atypical antipsychotic
- Dopamine system stabilizer
- Partial agonist on dopamine D2 and serotonin 5HT1A receptor, and antagonist on serotonin 5HT2A receptor
- Abilify Maintena® is a once-monthly injection indicated for:
- Treatment of schizophrenia in adult
- Bipolar I disorder (for maintenance monotherapy) in adult
| Formulation | Package | Strength | Colour / Appearance |
|---|---|---|---|
| Syringe | 1 vial/ box | 400 mg | Blue pre-filled dual chamber syringes |
| 300 mg | Yellow pre-filled dual chamber syringes |
REXULTI® (brexpiprazole tablets)
- Atypical antipsychotic
- Serotonin dopamine activity modulator (SDAM)
- Partial agonist on dopamine D2 and serotonin 5HT1A receptor, and antagonist on serotonin 5HT2A receptor
- REXULTI® is indicated for:
- Treatment of schizophrenia in adult
- Adjunctive treatment for major depressive disorder in adult
| Formulation | Package | Strength | Colour / Appearance |
|---|---|---|---|
| Tablets | 30 tablets/ box |
0.5 mg | Light orange, round; shallow convex; bevel-edged tablet |
| 1 mg | Light yellow, round; shallow convex; bevel-edged tablet |
||
| 2 mg | Light green, round; shallow convex; bevel-edged tablet |
||
| 3 mg | Light purple, round; shallow convex; bevel-edged tablet |
*Please refer to the full prescribing information for details